• Je něco špatně v tomto záznamu ?

Defining oligometastatic state in uro-oncological cancers

T. Fazekas, M. Miszczyk, A. Matsukawa, P. Nyirády, SF. Shariat, P. Rajwa

. 2024 ; 34 (4) : 261-265. [pub] 20240502

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24013377

PURPOSE OF REVIEW: Oligometastatic tumors illustrate a distinct state between localized and systematic disease and might harbor unique biologic features. Moreover, these tumors represent a different clinical entity, with a potential of long-term disease control or even cure, therefore they receive growing attention in the field of urologic oncology. RECENT FINDINGS: Currently, there is no consensus on the definition of oligometastatic prostate cancer, most experts limit it to a maximum of three to five lesions and involvement of no more than two organs, excluding visceral metastases. Quality data on oligometastatic bladder cancer is scarce, however, a consensus of experts defined it as a maximum of three metastatic lesions, either resectable or suitable for stereotactic therapy, without restrictions to the number of organs involved. As for kidney cancer, a maximum number of five metastases, without limitations to the location are defined as oligometastatic, with an important implication of timing of developing metastases since diagnosis of the primary tumor. SUMMARY: Defining oligometastatic state among urological tumors reflecting their distinct biological and clinical behavior is crucial to establish a sound framework for future clinical trials, and to facilitate guideline and policy formulation for improved patient care. Advancements in molecular imaging are expected to transform the field of oligometastatic urologic tumors in the future.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013377
003      
CZ-PrNML
005      
20240905133341.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000001184 $2 doi
035    __
$a (PubMed)38704827
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fazekas, Tamás $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology $u Centre for Translational Medicine, Semmelweis University, Budapest, Hungary
245    10
$a Defining oligometastatic state in uro-oncological cancers / $c T. Fazekas, M. Miszczyk, A. Matsukawa, P. Nyirády, SF. Shariat, P. Rajwa
520    9_
$a PURPOSE OF REVIEW: Oligometastatic tumors illustrate a distinct state between localized and systematic disease and might harbor unique biologic features. Moreover, these tumors represent a different clinical entity, with a potential of long-term disease control or even cure, therefore they receive growing attention in the field of urologic oncology. RECENT FINDINGS: Currently, there is no consensus on the definition of oligometastatic prostate cancer, most experts limit it to a maximum of three to five lesions and involvement of no more than two organs, excluding visceral metastases. Quality data on oligometastatic bladder cancer is scarce, however, a consensus of experts defined it as a maximum of three metastatic lesions, either resectable or suitable for stereotactic therapy, without restrictions to the number of organs involved. As for kidney cancer, a maximum number of five metastases, without limitations to the location are defined as oligometastatic, with an important implication of timing of developing metastases since diagnosis of the primary tumor. SUMMARY: Defining oligometastatic state among urological tumors reflecting their distinct biological and clinical behavior is crucial to establish a sound framework for future clinical trials, and to facilitate guideline and policy formulation for improved patient care. Advancements in molecular imaging are expected to transform the field of oligometastatic urologic tumors in the future.
650    _2
$a lidé $7 D006801
650    12
$a metastázy nádorů $7 D009362
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory močového měchýře $x patologie $x terapie $7 D001749
650    12
$a nádory ledvin $x patologie $x terapie $7 D007680
650    _2
$a nádory prostaty $x patologie $x terapie $7 D011471
650    _2
$a urologické nádory $x patologie $x terapie $x diagnóza $7 D014571
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Miszczyk, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Collegium Medicum - Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland
700    1_
$a Matsukawa, Akihiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Nyirády, Péter $u Department of Urology
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology $u Department of Urology, University of Texas Southwestern, Dallas, Texas, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Research Center for Evidence Medicine, Urology Department, Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Medical University of Silesia, Zabrze, Poland
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 34, č. 4 (2024), s. 261-265
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38704827 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133335 $b ABA008
999    __
$a ok $b bmc $g 2143281 $s 1225243
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 34 $c 4 $d 261-265 $e 20240502 $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace